Raising Funds through a Public Offering for Capital Expenditure, Investment in the Taiwanese Subsidiary and Debt Repayment
First written in FY2021. 3 of 4 entries say "Restated". Latest entry: FY2022-Q3.
12 other companies' latest entry also says "Restated".
- FY2022-Q3RestatedAnnual report
「Funds provided by financing activities amounted to ¥3,274,762 thousand, an increase of ¥2,562,900 thousand in proceeds from the previous fiscal year. This was mainly attributable to ¥4,909,454 thousand in proceeds from the issuance of shares.」
Proceeds of ¥4,909,454 thousand from the issuance of shares through the public offering were the main source of cash inflows from financing activities. The Company has continued to disclose the fundraising effect of the public offering conducted in the previous fiscal year. - FY2022-Q2RestatedAnnual report
「The issuance of 1,250,000 new shares through a public offering, for which payment was completed on 24 February 2021, increased stated capital by ¥2,470,000 thousand and the capital reserve by ¥2,470,000 thousand.」
The Company has continued to disclose the increase in stated capital and the capital reserve resulting from the issuance of 1,250,000 shares in the public offering conducted in the previous fiscal year. - FY2022-Q1RestatedAnnual report
「The issuance of 1,250,000 new shares through a public offering, for which payment was completed on 24 February 2021, increased stated capital by ¥2,470,000 thousand and the capital reserve by ¥2,470,000 thousand.」
The Company disclosed that the public offering conducted in the previous fiscal year involved the issuance of 1,250,000 shares and increased stated capital by ¥2,470,000 thousand and the capital reserve by ¥2,470,000 thousand. - FY2021First statedAnnual report
「We are also strengthening our equity capital, including by raising ¥4,940,000 thousand through a public offering with a payment date of 24 February 2021.」
The company issued 1,250,000 new shares in a public offering and raised total proceeds of ¥4,940,000 thousand. The funds were allocated to capital investment at domestic plants and elsewhere, investment in and loans to the consolidated Taiwanese subsidiary, and repayment of short-term borrowings from financial institutions.